CN100420391C - Health-care food with anti-oxidation and lowering weight functions - Google Patents
Health-care food with anti-oxidation and lowering weight functions Download PDFInfo
- Publication number
- CN100420391C CN100420391C CNB2006101632860A CN200610163286A CN100420391C CN 100420391 C CN100420391 C CN 100420391C CN B2006101632860 A CNB2006101632860 A CN B2006101632860A CN 200610163286 A CN200610163286 A CN 200610163286A CN 100420391 C CN100420391 C CN 100420391C
- Authority
- CN
- China
- Prior art keywords
- test
- group
- control group
- health food
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000003064 anti-oxidating effect Effects 0.000 title claims abstract description 23
- 235000013305 food Nutrition 0.000 title abstract description 10
- 230000006870 function Effects 0.000 title description 40
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 13
- 235000020333 oolong tea Nutrition 0.000 claims abstract description 13
- 239000000284 extract Substances 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 235000013402 health food Nutrition 0.000 claims description 45
- 239000007901 soft capsule Substances 0.000 claims description 38
- 239000010497 wheat germ oil Substances 0.000 claims description 13
- 229940087603 grape seed extract Drugs 0.000 claims description 12
- 235000002532 grape seed extract Nutrition 0.000 claims description 12
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007887 hard shell capsule Substances 0.000 claims description 2
- 241000209140 Triticum Species 0.000 abstract description 4
- 235000021307 Triticum Nutrition 0.000 abstract description 4
- 210000001161 mammalian embryo Anatomy 0.000 abstract description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229940087559 grape seed Drugs 0.000 abstract 1
- 229960001518 levocarnitine Drugs 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 108
- 241001465754 Metazoa Species 0.000 description 34
- 210000002966 serum Anatomy 0.000 description 31
- 230000009267 minimal disease activity Effects 0.000 description 26
- 238000000034 method Methods 0.000 description 25
- 230000037396 body weight Effects 0.000 description 24
- 102000019197 Superoxide Dismutase Human genes 0.000 description 23
- 108010012715 Superoxide dismutase Proteins 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 19
- 241000700159 Rattus Species 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000000577 adipose tissue Anatomy 0.000 description 14
- 230000005856 abnormality Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000007689 inspection Methods 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 230000008859 change Effects 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 9
- -1 Polyphenols compound Chemical class 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 238000004820 blood count Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 102000006587 Glutathione peroxidase Human genes 0.000 description 5
- 108700016172 Glutathione peroxidases Proteins 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 210000004003 subcutaneous fat Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 150000008442 polyphenolic compounds Chemical group 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 238000002562 urinalysis Methods 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 240000008415 Lactuca sativa Species 0.000 description 3
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000007872 degassing Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 229920002414 procyanidin Polymers 0.000 description 3
- 235000012045 salad Nutrition 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000009592 kidney function test Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 241000949648 Angulus Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 210000004490 abdominal subcutaneous fat Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011987 exercise tolerance test Methods 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 229940126707 lipid peroxidation inhibitor Drugs 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
A health-care food in the form of softgel, capsule, particle, tablet, or oral liquid for losing weight and antioxidizing is proportionally prepared from extract of grape seed, extract of oolong tea, levocarnitine, and wheat embryo bud oil.
Description
Technical field
The present invention relates to a kind of health food, is a kind of health food with fat-reducing and anti-oxidation function and preparation method thereof specifically.
Background technology
Along with the fast development of scientific and technological progress and social productive forces, people's living standard improves day by day, and obesity has developed into the popular chronic disease of modern society, becomes one of principal element that threatens human life's health.According to " science Times " message, The World Health Organization (WHO) has announced astonishing numeral a few days ago: the whole world more than 60 hundred million philtrums, there are more than 10 hundred million body weight for humans too high, and fat phenomenon has been not only " patent " disease of developed country, in less developed country, overweight and fat crowd's ratio also raises.WHO thinks that if go down by present trend development, by 2015, the whole world will have 1,500,000,000 body weight for humans overweight.
It is fat except " clothing, food, live, OK " to self brings inconvenience, also can produce than healthy people more substantial free radical in vivo, free radical has active chemical property, organic substance generation chain reaction in meeting and the cells in vivo, make proper endoperoxides compound bulk deposition, allow cell lose normal physiological function, majority present the early ageing phenomenon owing to cellular oxidation, thereby cause the generation of disease.
It is many to be used to the medicine or the food of losing weight at present, and its characteristics are respectively arranged, but Shang Weijian integrates the health food of fat-reducing and anti-oxidation function.
Summary of the invention
The purpose of this invention is to provide a kind of health food with fat-reducing and anti-oxidation function
Health food of the present invention is by pure natural raw material grape seed extract, oolong tea extract, l-cn, wheat embryo wet goods, and forms through scientific composition is refining with reference to the modern pharmacological research achievement.
The main component of grape seed extract is polyphenol compound-glucosidase procyanidins.OPC is a kind of antioxidant radical scavenger and lipid peroxidation inhibitor, has the ability of very strong antioxidation activity and removing free radical.Experiment showed, that the grape seed extract OPC can effectively remove multiple free radical, protection DNA avoids the oxidative damage that OH causes, is good antioxidants.Experiment also shows, grape pip procyanidin can obviously reduce rat body weight, body fat when serum TC, TG level, and the experimental session animal activity normally, nothing is obviously suffered from diarrhoea and the phenomenon of appetite-suppressing takes place, and illustrates that grape seed extract PC has the effect that suppresses the animal quality growth preferably.
Being rich in active factors-Tea Polyphenols compound in the oolong tea, is desirable natural antioxidant.Can promote lipolysis, reduce in the blood and the lipid content in the adipocyte.Clinical trial shows: 75 routine simple obesities are by drinking oolong tea, efficient 52%, the obvious effective rate 15% that loses weight, total effective rate 67%.When using ultrasonic method to measure experimenter's abdominal subcutaneous fat, find, take oolong tea continuous 6 weeks and can make subcutaneous fat degree of capturing reduce 13%, and overweight people's abdominal circumference also is significantly improved.Test shows that also Tea Polyphenols has the function of removing active oxygen radical, and its activity is 4.93 times of equivalent VC.Tea Polyphenols can also suppress peroxidatic reaction of lipid except having direct removing active oxygen radical, and can pass through metal-chelating, strengthens the antioxidation of other antioxidants.
L-cn is the important nutrition fortifier that human body needs, safety, good stability.Experiment showed, that l-cn can quicken the transhipment of aliphatic acid, strengthen the effect that consumes aliphatic acid, impel the fat of cylinder storage to reduce, obviously alleviate the rat obese degree.Adopt blind method observation l-cn that the influence of fat teenager's body weight is proved that additional l-cn can improve the utilization of body to fat, promote the burning of body fat.
Wheat-germ oil is to be a kind of grain germ oil that raw material is produced with the wheat embryo, contains abundant insatiable hunger and closes aliphatic acid, vitamin E and 28 carbon alcohol.Have the ability of removing free radical, the free radical chain reactions that can interrupt running up suppresses the formation of polyunsaturated fatty acid peroxyester, alleviates the operation of membrane structure and aging, safeguards the normal operation of cell function, has tangible antioxidation.Zoopery shows: wheat-germ oil can obviously reduce the level of animal subject serum total cholesterol and serum LDL-C, has the function of regulating blood fat, helps to strengthen weight losing function.The existence of natural VE has improved the security and the stability of wheat-germ oil in the wheat-germ oil, can play antioxidation in the present invention, and therefore, the present invention adopts the matrix of wheat-germ oil as soft capsule.
The reasonable combination of above-mentioned each raw material makes health food of the present invention have excellent fat-reducing and anti-oxidation function.
Health food of the present invention is made by the raw material of following weight parts:
Grape seed extract 5-20 part,
Oolong tea extract 5-20 part,
L-cn 5-20 part,
Wheat-germ oil 20-80 part.
The preparation method that above-mentioned each raw material is made health food of the present invention is:
(1) chooses grape seed extract, oolong tea extract, l-cn, the wheat-germ oil that conforms to quality requirements, test, after meeting the requirements, leave and take standby according to respective standard;
(2) grape seed extract, oolong tea extract, l-cn, the wheat-germ oil of described weight proportion mixed.
Health food of the present invention can add conventional auxiliary material required when preparing different dosage form, adopts the conventional method of Chinese medicine preparation to be prepared into any conventional oral formulations, as soft capsule, hard shell capsules, granule, tablet, oral liquid etc.
Health food of the present invention shows through effect experiment, toxicological security and stability experiment, remarkable, definite, nontoxic, the good stability of its effect, take confirmation through majority, a kind of really health food that has strong fat-reducing and anti-oxidation function and can eat for a long time.Have advantages such as prescription is unique rationally, bioavilability is high, function is remarkable, have no side effect, absorb rapidly, taking dose is little.
The specific embodiment
Below in conjunction with embodiments of the invention and test example the present invention is further described, but the present invention is not limited to embodiment, those of ordinary skills do some modification with technical solution of the present invention, still in protection domain of the present invention.
Embodiment 1-5: health food preparation of soft capsule of the present invention
The weight proportion of each raw material sees Table 1 among each embodiment.
Preparing the used auxiliary material of health food soft capsule of the present invention is the raw material of following weight parts:
Beeswax 0.5-2 part.
Table 1
| Embodiment number | Grape seed extract (kg) | Oolong tea extract (kg) | L-cn (kg) | Wheat-germ oil (kg) | Beeswax (kg) |
| 1 | 5 | 5 | 5 | 20 | 0.5 |
| 2 | 13 | 8 | 10 | 35 | 0.3 |
| 3 | 10 | 12 | 16 | 60 | 2 |
| 4 | 25 | 15 | 19 | 75 | 1 |
| 5 | 20 | 20 | 20 | 80 | 2 |
The source of primary raw material and quality standard are as follows among the embodiment:
1, grape seed extract Tianjin spike natural products Co., Ltd produces, and accord with Q/12BJ4963-2002 stipulates specification requirement, procyanidin content 95%.
2, oolong tea extract Hunan Jinnong Biological Resources Co., Ltd. produces, and accord with Q/OBEA001-2003 stipulates specification requirement, polyphenol content 〉=30%.
3, the good bright International Trade Corporation production in l-cn Tianjin meets the specification requirement of CB17787-1999 regulation, carnitine content 〉=30%.
4, wheat-germ oil Xuzhou Epson thing engineering company produces, and accord with Q/320307XAC01-2001 stipulates specification requirement.
Health food preparation of soft capsule method of the present invention is (with embodiment 3 is example, and other embodiment is except that raw material consumption difference, and the preparation method is substantially the same manner as Example 3):
1, chooses grape seed extract, oolong tea extract, l-cn, the wheat-germ oil that conforms to quality requirements, test, after meeting the requirements, leave and take standby according to respective standard.
2,60kg wheat-germ oil, 2kg beeswax are placed material-compound tank, after 35 ℃ of mixing of constant temperature are stirred, again 10kg grape seed extract, 12kg oolong tea extract, 16kg l-cn are added wherein, continue to stir to make in 20-30 minute and mix, 100 mesh sieves are squeezed in the degassing tank after filtering, and are under the 60-70mmHg vacuum at 35 ℃ of constant temperature, pressure, stir 30-45 minute at a slow speed with the degassing, squeeze into heat-preserving container after the degassing and get soft capsule content, be incubated under 35 ℃ of conditions in order to pelleting.
3, technology prepares the soft capsule packaging material routinely, and soft capsule content is sent into the pellet press pill, gets health food soft capsule of the present invention.
Test example 1: the anti-oxidation function check of health food of the present invention
Anti-oxidation function for examination health food of the present invention, with embodiment 3 gained 5kg health food soft capsule of the present invention (hereinafter to be referred as: soft capsule) send Harbin Medical University, according to " health food function assessment assessment process and method of inspection standard ", check its anti-oxidation function.Survey report is as follows:
1 materials and methods
1.1 sample: given the test agent soft capsule (lot number 040607) content is brown liquid, and is water insoluble, is dissolved in salad oil, the examination by sensory organs no abnormality seen.
1.2 experimental technique
1.2.1 animal used as test:
A cleaning level male Wistar old rats 40 (more than 12 monthly ages) be the test group animal, and 10 of 3 monthly ages cleaning grade male Wistar rats are as the normal control treated animal, all available from institute of oncology, Heilongjiang Province animal center.Aged group is divided into 4 groups at random by the serum MDA level, 10 every group.
1.2.2 dosage design
Test is divided into 5 groups, 10 of every treated animals, and wherein old rats is 4 groups, comprises aged control group and 3 test group; Other establishes a normal control group.Soft capsule human body recommended amounts is everyone 2.0g every day, and as becoming body weight for humans in 60kg, then RD is equivalent to the 0.033g/kg body weight.The design of animal experiment dosage is respectively 5,10,30 times that the people recommends consumption, and then basic, normal, high dosage is respectively the 0.17g/kg body weight, 0.33g/kg body weight and 1.00g/kg body weight.Given the test agent is that solvent is made into various dose concentration with the salad oil, irritate stomach volume filling stomach by the 10ml/kg body weight and give each test group animal, and control animals gives the isometric(al) salad oil, all animal continuous irrigation stomaches 30 days.
1.2.3 reagent and instrument
MDA measures kit, SOD detection kit and GSH-Px detection kit and all purchases and build up bio-engineering research institute in Nanjing.Instrument is 722 type spectrophotometers.
1.2.4 experimental technique
Each treated animal is irritated the stomach various dose by designed dosage and tried thing every day, weighs weekly once, adjusts the stomach amount of irritating.Give continuously soft capsule sacrificed by decapitation animal after 30 days, get blood and prepare serum, finished lipid peroxide catabolite MDA (MDA) assay (TBA fluorescence method) in the serum, superoxide dismutase (SOD) vitality test (hydroxylamine assay) and glutathione peroxidase (GSH-Px) vitality test (DTNB method) in 24 hours, experimental technique is pressed the operation of kit specification.
1.3 data are handled
The gained data is carried out statistical disposition with variance analysis, carries out homogeneity test of variance earlier, and variance is neat, then calculates the F value, and the F value is more than or equal to F
0.05The time, organize a mean with three test group and old-age group and compare in twos; The data of abnormal or heterogeneity of variance are carried out the conversion of suitable variable, wait to satisfy normal state or variance are neat require after, add up with the data after changing.
2 results
2.1 influence to the serum mda content
Old rats is carried out random packet by the serum MDA level, and each treated animal serum MDA level sees Table 2
Irritate stomach and give the rats in test groups soft capsule after 30 days, lipid peroxide catabolite MDA content measurement result sees Table 3 in the animal blood serum.
From table 3 result as seen, the catabolite MDA level of aged control rats serum lipid peroxide is higher than normal control group (P＜0.01), and give soft capsule after 30 days, test group animal blood serum mda content obviously reduces, and middle and high dosage treated animal is compared with aged treated animal all has significant difference (p＜0.05).
Table 2
| Group | Dosage (g/kg.bw) | Number of animals (only) | MDA content (mmol/L) | F | p |
| The normal control group | - | 10 | 3.58±0.827 | ||
| Low dose group | 0.17 | 10 | 5.36±1.166 | ＞0.05 | |
| Middle dosage group | 0.33 | 10 | 5.49±1.246 | ＞0.05 | |
| High dose group | 1.00 | 10 | 5.34±1.199 | ＞0.05 | |
| Aged control group | - | 10 | 5.80±2.273 | 6.250 |
Table 3
| Group | Dosage (g/kg.bw) | Number of animals (only) | MDA content (mmol/L) | The q value | p |
| The normal control group | - | 10 | 3.68±0.88 ＊＊ | 5.69 | ＜0.01 |
| Low dose group | 0.17 | 10 | 4.78±1.60 | ||
| Middle dosage group | 0.33 | 10 | 4.34±1.21 ＊ | 3.96 | ＜0.05 |
| High dose group | 1.00 | 10 | 4.26±1.04 ＊ | 4.17 | ＜0.05 |
| Aged control group | - | 10 | 5.86±1.20 |
Annotate:
*With aged control group than p＜0.05
*With aged control group than p＜0.01
2.2 influence to the rat blood serum antioxidase activity
Irritate stomach and give test group animal soft capsule after 30 days, the measurement result of animal blood serum superoxide dismutase (SOD) vigor and glutathione peroxidase (GSH-Px) vigor sees Table 4.
By table 4 result as seen, aged control rats serum activity of SOD and GSH-Px vigor are starkly lower than the normal control group, (all p＜0.01).When giving soft capsule after 30 days, two anti-oxidant vigors of three test group all raise, and still, three test group SOD vigor are compared with aged control group does not have significant difference; Middle and high dosage treated animal serum GSP-Hx vigor is compared with aged control group all has significant difference (p＜0.05), shows that soft capsule has the effect of rising GSP-Hx vigor.
Table 4
| Group | Dosage (g/kg.bw) | Number of animals (only) | SOD vigor (u/ml) | The q value | p | GSH-Px vigor (u/ml) | The q value | p |
| The normal control group | - | 10 | 282.0±27.3 ＊＊ | 4.98 | ＜0.01 | 174.0±22.0 ＊ | 5.32 | ＜0.01 |
| Low dose group | 0.17 | 10 | 254.0±35.4 | 148.0±30.9 | ||||
| Middle dosage group | 0.33 | 10 | 260.0±29.2 | 165.0±36.4 ＊ | 4.32 | ＜0.05 | ||
| High dose group | 1.00 | 10 | 263.0±27.0 | 168.0±24.9 ＊ | 4.59 | ＜0.05 | ||
| Aged control group | - | 10 | 238.0±21.9 | 128.0±18.0 |
Annotate: compare p＜0.05 with aged control group
*Compare p＜0.01 with aged control group
Conclusion:
Tried old rats and given health food soft capsule of the present invention after 30 days, middle and high dosage treated animal mda content obviously reduces (all＜0.05), illustrate that given the test agent has the reduction lipid peroxidation, middle and high dosage treated animal serum paddy Guang peptide peroxidase activity obviously raises (all＜0.05), illustrates that given the test agent has the effect of rising antioxidase activity.According to anti-oxidation function zoopery criterion as a result in " health food function assessment assessment process and method of inspection standard ", assert health food soft capsule Wheat Protein of the present invention.
Test example 2: the anti-oxidation function human feeding trial of health food of the present invention
Anti-oxidation function for examination health food of the present invention, with 80000 (0.5g/ grain) health food soft capsules of the present invention of embodiment 3 gained (hereinafter to be referred as: soft capsule) send the disease prevention and control center, Hunan Province, according to " health food check and assessment technique standard " (version in 2003), check its anti-oxidation function.Survey report is as follows:
1 material and method
1.1 sample
No. 1, No. 2, the two is in full accord on packing, outward appearance, color and luster and mouthfeel, and one of them is a soft capsule, and another is a placebo, four of oral every days.
1.2 the experimenter selects
1.2.1 the standard of including in: 120 experimenters are selected from Changsha high mountain foot of a hill or mountain community, male or female.Age 45-65 year, physical condition is good, does not have obvious brain, the heart, liver, kidney, blood illness, does not have the trial volunteer of the history of taking medicine for a long time and guarantees to cooperate.
1.2.2 experimenter's exclusion standard: gestation or women breast-feeding their children, to the health food allergy sufferers; Merge to have the inclination, serious disease patients such as liver, kidney and hemopoietic system; Take the article relevant in a short time, have influence on judgement person as a result with being tried function; Do not meet the standard of including in, edible in accordance with regulations given the test agent can't be judged effect or data not umbra sound effect or security judgement person.
1.3 experimental design and grouping
Adopt two kinds of control design between self and group.Be divided into soft capsule test-meal group and placebo at random by experimenter's serum MDA (MDA), hepatocuprein (SOD), glutathione peroxidase (GSH-Px) level, and consider to influence result's principal element such as age, sex etc. as far as possible, carry out the harmony check, with the comparativity between the assurance group, carry out the test-meal test by double-blind study.
1.4 test method
The 120 routine trial volunteers that will meet the standard of including in and guarantee cooperate are divided at random and are subjected to examination group and control group.Be subjected to examination group and control group all to take 4 of sample every days, observed continuously 160 days.Duration of test does not change original eating habit, normal diet.
2 observation index
Each measures once every observation index when test-meal on-test and end.
2.1 safety indexes
General physical examination: perquisition and consult the healthy card of experimenter before the test, understand experimenter's situations such as spirit, sleep, diet, stool and urine, blood pressure, all experimenters are carried out conventional physical examination and necessary laboratory examination; Routine blood test: red blood cell count(RBC), white blood cell count(WBC), content of hemoglobin mensuration etc.; Routine urinalysis: ph value, leucocyte, glucose in urine etc.; Stool for routine: worm's ovum inspection etc.; Liver function test: total serum protein (TP), albumin (ALB), glutamic-pyruvic transaminase (ALT), cholesterol (CHOL), triglycerides (TG) are measured; Kidney function test: serum urea nitrogen (BUN), creatinine (Cr), blood sugar (GLU) are measured; Inspections such as electrocardiogram, Abdominal B type ultrasonography, Chest X-rays.
2.2 effect index
2.2.1 lipid peroxide content: variation and the MDA rate of descent of MDA before and after the viewing test.
MDA * 100% before MDA rate of descent=(MDA-test back MDA before the test)/test
2.2.2 hepatocuprein: variation and the SOD rate of rise of SOD before and after the viewing test.
SOD * 100% before SOD rate of rise=(SOD before the SOD-test of test back)/test
2.2.3 glutathione peroxidase: the variation of GSH-Px and the rate of rise of GSH-Px before and after the viewing test.
GSH-Px * 100% before the rate of rise of GSH-Px=(GSH-Px before the GSH-Px-test of test back)/test
3. statistical procedures
Data result represents with mean ± standard deviation, self paired data adopts paired t-test, between test group and the control group under the prerequisite of homogeneity of variance, mean relatively adopts t check in groups, otherwise adopt the t check after carrying out satisfying homogeneity of variance after variable transforms, if variance is still uneven, adopt rank test.
4. the result judges
4.1 between group statistical significance is arranged more all after each effect observation index test front and back self comparison and the test-meal, can judge this index positive.
4.2 each experimental result positive in lipid peroxide content, hepatocuprein, three experiments of glutathione peroxidase, the decidable given the test agent has the anti-oxidation function effect.
5. result
Double-blind study is observed and is finished to make known: take No. 1 person and be soft capsule, take No. 2 persons and be placebo.
5.1 ordinary circumstance: initial trial crowd's test group 60 examples, control group 60 examples, after test in 160 days, test group has 2 routine experimenters not screened out entirely because of judging curative effect or data, control group has 1 routine experimenter to take because of interruption to be subjected to test product, last efficiency test crowd test group 58 examples, control group 59 examples.Before and after the test-meal, experimenter's mental status, sleep state, stool and urine situation no abnormality seen.The test-meal group: man/woman is 17/41, and the age is 53.03 ± 6.20, control group: man/woman is 17/42, and the age is 53.12 ± 5.45.
5.2 security is observed
5.2.1 blood and hepatic and renal function
See Table 5,6.Eat and tried thing after 160 days, all in normal range (NR), the prompting soft capsule does not have obvious damage to body health for test-meal group and control group blood picture, routine urinalysis, stool routine examination and biochemical indicator.
5.2.2 electrocardiogram, Abdominal B type ultrasonography, Chest X-rays inspection are all in normal range (NR).
5.3 effect is observed
Serum MDA, the horizontal situation of change of SOD, GSH-Px see Table 7,8,9 before and after the test-meal test.Before the test, control group and test-meal group serum MDA, SOD, GSH-Px level compare, and the P value is pointed out between two groups to have comparativity all greater than 0.05.Test back test-meal group serum GSH-Px vigor is than control group significantly raise (P＜0.05).Test-meal group serum GSH-Px improves 10.71% before the experiment after the test-meal, and both comparing differences have conspicuousness (P＜0.05), and serum MDA reduces by 0.82% before the test, and serum activity of SOD raises 2.60% before the test.
Routine blood test index situation of change before and after table 5 test-meal (x ± s)
Changes of biochemical indexes situation before and after table 6 test-meal (x ± s)
Conclusion:
The experimenter takes and is tried thing after 160 days, the result shows: test-meal group SOD in serum, GSH-Px vigor improve 2.60%, 10.71% before the test respectively after the test-meal, reduce by 0.82% before serum MDA is tried, wherein the GSH-Px vigor significantly improves (P＜0.05) before the test.Test back test-meal group serum GSH-Px vigor is than control group significantly raise (P＜0.05).Safety indexes such as blood, urine, stool routine examination, hepatic and renal function, electrocardiogram, B ultrasonic are all in normal range (NR) before and after the test-meal, and do not find bad reaction.The The above results prompting submitted sample GSH-Px vigor experimental result positive has the anti-oxidation function effect.
Serum MDA, SOD, GSH-Px level self are relatively before and after table 7 test-meal
Annotate:
*With comparison P＜0.05 before the test-meal
Two groups of serum MDAs, SOD, GSH-Px levels compare after table 8 test-meal
| Index | Control group | The test-meal group | P |
| MDA(nmol/mL) | 3.71±0.60 | 3.67±0.74 | ＞0.05 |
| SOD(NU/ml) | 131.02±11.20 | 133.37±12.70 | ＞0.05 |
| GSH-Px (unit of activity) | 105.88±10.15 | 114.15±13.73 | ＜0.05 |
Serum MDA, SOD, GSH-Px rate of change before and after table 9 test-meal
| Index | Control group | The test-meal group |
| MDA reduced rate (%) | -0.82 | 0.82 |
| SOD rate of rise (%) | 0.82 | 2.60 |
| GSH-Px rate of rise (%) | 2.71 | 10.71 |
Test example 3: the weight losing function test of health food of the present invention
Weight losing function for examination health food of the present invention, with embodiment 3 gained 0.5g/ grains * 12 * 1335 plates health food soft capsule of the present invention (hereinafter to be referred as: soft capsule) send monitoring of hygiene inspection center, Jilin Province, according to " health food check and assessment technique standard " (version in 2003), in the second portion function assessment evaluation test method of health food function assessment assessment process and method of inspection standard, " 15, the weight losing function method of inspection " check its weight losing function.Survey report is as follows:
One, test objective: detect and be subjected to the influence of food to fat body weight and body fat content
Two, materials and methods:
1 sample proterties: oval soft capsule, content are brown liquid.
2 animals used as test: 50 of cleaning level male Wistar kind rats, body weight 136.1～153.6 true g are provided animal production licence number: SCXK-(Ji) 2003-0001 by preclinical medicine institute of Jilin University zoopery center.
Feeding environment: room temperature 20-22 ℃, relative humidity are 55-65%, and single cage is raised.
Feed resource: the living animal used as test feed factory of Changchun Lvyuan District benefit, production licence number: SCXK-(Ji) 2003-2004; This animal housing occupancy permit number: the moving word 10-7201 of doctor.
3 high fat nutrient fodders: basal feed 80%, lard 10%, yolk powder 10%.
4 test methods:
4.1 give the object space formula of being tried: per os is irritated stomach.
4.2 dosage design: recommended amounts is every day 2 times, each 2, and every 0.5g, become body weight for humans to press the 60kg design, then every day 0.033g/kgBW, be the dosage of basic, normal, high three dosage groups with 1,5,25 times of recommended amounts, promptly 0.033,0.167,0.833g/kgBW.The thing that tried of each dosage group is diluted to desired concn with soya-bean oil.
4.3 operating procedure:
Choose 50 of healthy male Wistar rats, be divided into 5 groups at random by body weight, 10 every group, promptly blank group, model control group and basic, normal, high three are tried agent amount group.Model control group and three dosage groups give high fat nutrient fodder, and the blank group gives basal feed.Three test group are irritated the thing that tried that stomach gives various dose, and two control groups filling stomach gives the soya-bean oil with volume, irritates the stomach amount and is 1ml/100gBw.Experimental session, it is principle that the animal feed administered dose is eaten up with most of animals, weighs when experiment finishes, cuts open the belly and get body fat (testis and perinephric fat pad) and weigh, and calculates fat/body ratio.All experimental datas all adopt " SPSS 10.0 " software to carry out variance analysis.
Three, result
3.1 soft capsule sees Table 10 to the influence of rat body weight, food ration, food overall utilization.
The influence of table 10 pair rat body weight, food ration, food overall utilization
Annotate: blank group and model control group compare: #P＜0.05, ##P＜0.01
Each experimental group and fat model control group compare:
*P＜0.05,
*P＜0.01
From table 10 as seen, the model control group rat body weight is higher than the blank group, difference has highly significant, the fat model manufacturing success of animal is described, all be lower than model control group and feed each rats in test groups body weight of raising high fat nutrient fodder simultaneously, learn check by statistics, middle and high dosage group rat body reason is lower than model control group and difference has conspicuousness (P＜0.05).There are no significant for difference between blank group and model control group and each the dosage group rat food ration.
Four conclusions:
This zoopery is established 0.033g/kg, 0.167g/kg, 0.833g/kgBW as basic, normal, high three dosage groups, be equivalent to 1 times, 5 times, 25 times of human body recommended amounts respectively, result of the test shows: test model control group body weight in latter stage is higher than the blank group, and difference has conspicuousness (P＜0.01), and fat model establishment is described; The body weight of testing last middle and high dosage group is lower than model control group and difference has conspicuousness (P＜0.01), and the body fat of high dose group weighs less than control group, the soft capsule animal weight losing function result of the test positive.
Test example 4: the weight losing function human feeding trial of health food of the present invention
Weight losing function for examination health food of the present invention, with embodiment 3 gained 0.5g/ grains * 12 * 1335 plates health food soft capsule of the present invention (hereinafter to be referred as: soft capsule) send monitoring of hygiene inspection center, Jilin Province, according to " health food check and assessment technique standard " (version in 2003), in the second portion function assessment evaluation test method of health food function assessment assessment process and method of inspection standard, " the 15 weight losing function method of inspection " makes the weight losing function human feeding trial.Survey report is as follows:
1 material and method
1.1 the oval soft capsule of sample, content is a brown liquid, the 0.5g/ grain.
1.2 study subject is selected the trial volunteer of simple obesity, through the just clinical examinations such as routine, B ultrasonic, electrocardiogram and the fluoroscopy of chest of X line of hepatic and renal function, blood urine, get rid of merge intentionally, serious disease persons such as liver, kidney and hemopoietic system; Get rid of the mental patient; Get rid of and take the article relevant in a short time, have influence on judgement person the result with being tried function; And constitutional index (BMI) 〉=30, or total fatty percentage reaches man＞25%, woman＞30%, totally 100 as study subject.
1.3 taking dose and method recommend dose to be everyone (adult) every day 2 times, each 2, are consistent before experimenter's daily life, eating habit and amount of exercise and the test during the test-meal.
1.4 experimental design is according to weight losing function human feeding trial regulation in " the health food function assessment is estimated and method of inspection standard " of Ministry of Public Health's version in 2003, the experimenter adopts two kinds of control design between self and group.According at random, the requirement of double blinding divides into groups, body weight, body fat weight by the experimenter are divided into test-meal group and control group at random, and consider to influence result's principal element such as age, sex, diet, moving situation etc. as far as possible, have comparativity to guarantee two groups.Test group is taken given the test agent, test group 50 people, and the age, wherein the male sex was 15 between 27 years old-45 years old, 35 of women, control group adopts blank, control group 50 people, the age is between 27 years old-45 years old, wherein the male sex is 14,36 of women, and it is 35 days that sample gives the time.Guarantee during off-test that every group of experimenter's number is no less than 50 examples,, two groups of means are relatively adopted t-check in groups, when P＜0.05, think that difference has conspicuousness the pairing t-check of own control data before and after experimentizing.
1.5 key instrument lever scale (RGZ-120 type, Wujin, Jiangsu Province city weighing apparatus factory), body composition analyzer (Model 310e), cycle ergometer (Model 818E), heart rate monitor.
1.6 observation index
1.6.1 safety indexes
Situations such as general symptom spirit, sleep, diet, stool and urine, heart rate, blood pressure; Blood, urine, just routine inspection; Liver, kidney function test; Electrocardiogram, Abdominal B type ultrasonography (liver, courage, pancreas, spleen, kidney) are checked, the Chest X-rays of X line; Blood uric acid, urine ketoboidies.
1.6.2 its functional attributes
1.6.2.1 measure height and weight and basis of calculation overweight degree:
Adult SBW (kg)=[height (cm)-100] * 0.9
1.6.2.2 body fat total amount (kg) and fatty percentage (%) are measured;
Body composition analyzer is measured body fat content.
1.6.2.3 subcutaneous fat thickness measuring:
B ultrasonic method (analytical unit is mm) is measured, and measures the site for 1 and sees Table 11:
Table 11
| The A point | Right deltoid muscle lower edge arm outside mid-point |
| The B point | Right angulus inferior scapulae |
| The C point | The other 3cm of right navel |
| The F point | Right bone Ant sup |
1.6.2.4 waistline, abdominal circumference and hip circumference are measured:
Adopt tape measure (cm) to measure.Waistline is measured the abdomen girth of flat navel, and hip circumference is measured the girth with both sides greater trochanter of femur level.
2 results
2.1 study subject screening is included standard in according to the experimenter, 100 experimenter's objects are all as the experimenter, the equal unmanned ablation experiment of duration of test test group and control group, the requirement of being in order.
2.2 subjective symptoms during taking, finds no bad reaction according to experimenter's readme situation, mental status, sleep, stool and urine situation no abnormality seen before and after the experimenter tests.
2.3 safety indexes
2.3.1 electrocardiogram, B ultrasonic, Chest X-rays and other
Experimenter's electrocardiogram, the fluoroscopy of chest of X line, Abdominal B type ultrasonography check result show no obvious abnormalities before the test, heart rate, blood pressure, urine, just routine inspection no abnormality seen variation before and after the test, the check result of twice heart rate, blood pressure all in range of normal value, sees Table 12.
Table 12 couple human heart rate, blood pressure, routine urinalysis, the just influence of routine
| Number | Heart rate (inferior/min) | Systolic pressure (mmHg) | Diastolic pressure (mmHg) | Routine urinalysis | The urine ketoboidies | Just conventional | |
| Range of normal value | 60～100 | 90～140 | 60～90 | - | - | - | |
| Test group (preceding) | 50 | 77.6±11.7 | 111.1±8.0 | 76.3±5.6 | No abnormality seen | - | No abnormality seen |
| Test group (back) | 50 | 76.6±10.8 | 109.2±8.7 | 76.0±6.6 | No abnormality seen | - | No abnormality seen |
| Control group (preceding) | 50 | 77.4±12.7 | 112.9±9.3 | 78.0±6.5 | No abnormality seen | - | No abnormality seen |
| Control group (back) | 50 | 79.7±12.2 | 112.1±7.6 | 77.0±7.6 | No abnormality seen | - | No abnormality seen |
2.3.2 blood routine inspection
The measurement result of experimenter's red blood cell count(RBC), white blood cell count(WBC), content of hemoglobin, platelet count all in range of normal value, does not have significantly change before and after the test, sees Table 13.
The measurement result of experimenter's lymph percentage (LYMP%), monocyte percentage (MONO%), neutrophil leucocyte percentage (NEUT%), acidophil percentage (EO%), basocyte percentage (BASO%) increases in range of normal value before and after the test, do not have significantly change, see Table 14.
The influence (1) of table 13 pair human body routine blood test
| Number | Red blood cell count(RBC) (10 12/L) | White blood cell count(WBC) (10 9/L) | Content of hemoglobin (g/L) | Platelet count (10 9/L) | |
| Range of normal value | 3.5～5.5 | 4.0～10.0 | 110～160 | 100～300 | |
| Test group (preceding) | 50 | 4.7±0.3 | 6.6±1.3 | 140.9±12.7 | 228.4±51.3 |
| Test group (back) | 50 | 5.0±0.5 | 6.5±1.2 | 141.8±13.9 | 292.0±75.9 |
| Control group (preceding) | 50 | 4.8±0.4 | 6.9±1.4 | 143.0±13.5 | 225.7±54.4 |
| Control group (back) | 50 | 5.1±0.5 | 6.7±1.0 | 145.6±13.2 | 284.9±86.7 |
The influence (2) of table 14 pair human body routine blood test
| Number | LYMP％ | MONO％ | NEUT％ | EO％ | BASO％ | |
| Range of normal value | 20～40 | 3～8 | 50～70 | 0.5～5 | 0～1 | |
| Test group (preceding) | 50 | 34.4±9.5 | 7.7±2.0 | 55.4±9.9 | 2.1±1.8 | 0.4±0.2 |
| Test group (back) | 50 | 33.6±6.7 | 7.2±1.7 | 56.8±7.4 | 2.1±1.4 | 0.4±0.2 |
| Control group (preceding) | 50 | 33.7±8.6 | 7.7±1.8 | 56.2±8.8 | 2.0±1.8 | 0.4±0.2 |
| Control group (back) | 50 | 33.8±7.1 | 7.1±1.7 | 56.7±7.8 | 2.0±1.3 | 0.4±0.2 |
2.3.3 blood parameters is measured
The every biochemical indicator creatinine of experimenter (CRE), urea nitrogen (BUN), uric acid (URIC), glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminease (AST) all in normal range (NR), do not have significantly change before and after the test, see Table 15.
The influence (1) of table 15 pair blood of human body biochemistry
| Number | CRE (mmol/L) | BUN (mmol/L) | URIC (umol/L) | ALT (U/L) | AST (U/L) | |
| Range of normal value | 40～120 | 2.5～7.0 | 90～420 | 0～40 | 0～40 | |
| Test group (preceding) | 50 | 72.8±12.5 | 4.5±1.1 | 246.5±60.2 | 19.4±10.6 | 20.6±6.1 |
| Test group (back) | 50 | 69.6±10.1 | 4.3±1.3 | 244.9±58.7 | 16.4±7.0 | 22.6±4.9 |
| Control group (preceding) | 50 | 70.1±12.7 | 4.9±1.2 | 246.6±48.2 | 17.3±9.6 | 22.0±5.2 |
| Control group (back) | 50 | 72.7±11.7 | 4.4±1.3 | 261.8±71.0 | 18.7±11.3 | 23.7±4.7 |
The every biochemical indicator total protein of experimenter (TP), albumin (ALB), globulin (G), albumins/globulins ratio (A/G) before and after the test, all in range of normal value, do not have significantly and change, the results are shown in Table 16.
The influence (2) of table 16 pair blood of human body biochemistry
| Number | TP (g/L) | ALB (g/L) | G (g/L) | A/G | |
| Range of normal value | 60～80 | 35～35 | 20～35 | 1.5～2.5 | |
| Test group (preceding) | 50 | 76.7±5.1 | 45.9±3.0 | 30.7±3.2 | 1.5±0.2 |
| Test group (back) | 50 | 75.1±3.6 | 48.1±2.4 | 27.1±3.4 | 1.8±0.3 |
| Control group (preceding) | 50 | 76.7±5.1 | 46.2±2.9 | 30.5±3.6 | 1.5±0.2 |
| Control group (back) | 50 | 74.9±3.8 | 47.8±3.0 | 27.1±3.7 | 1.8±0.3 |
2.3.4 exercise tolerance test
Test back experimenter's maximal oxygen uptake does not reduce, and illustrates that experimenter's endurance (being aerobic capacity) does not descend, and sees Table 17.
The influence of table 17 pair human body tolerance
| Number | HRrest (inferior) | Motion stable state heart rate (inferior) | Recovered heart rate (inferior) in 1 minute | Load (kg.m/min) | Maximal oxygen uptake (L) | |
| Test group (preceding) | 50 | 77.6±11.7 | 134.2±8.9 | 107.8±7.2 | 366.6±44.3 | 2.3±0.4 |
| Test group (back) | 50 | 76.6±10.8 | 136.4±7.2 | 109.9±6.5 | 372.2±40.2 | 2.3±0.3 |
| Control group (preceding) | 50 | 77.4±12.7 | 134.8±9.2 | 106.0±6.6 | 353.2±37.8 | 2.3±0.4 |
| Control group (back) | 50 | 79.7±12.2 | 133.8±7.8 | 108.2±7.0 | 368.6±43.2 | 2.4±0.3 |
| Pairing t-check (t value) | - | 0.454 | 1.320 | 1.597 | 0.632 | 1.004 |
| Pairing t-check (p value) | - | 0.652 | 0.193 | 0.117 | 0.530 | 0.321 |
| T-check (t value) in groups | - | 1.317 | 1.738 | 1.244 | 0.431 | 1.622 |
| T-check (p value) in groups | - | 0.191 | 0.085 | 0.217 | 0.667 | 0.108 |
Annotate: pairing t-verifies as before and after the test group relatively, and t-verifies as test group and compares with control group in groups
2.4 its functional attributes
2.4.1 body weight, body fat total amount and fatty percentage are measured, and see Table 18.
2.4.2 subcutaneous fat thickness and body enclose mensuration, see Table 19.
3 conclusions
100 routine simple obesity experimenters take health food soft capsule of the present invention after 35 days on request, test-meal group weight average decline 2.0 ± 2.8kg, body fat content decline 1.8 ± 1.5kg, waistline decline 2.8 ± 1.5cm, navel side and bone Ant sup reduce 1.7 ± 0.7mm and 1.4 ± 0.8mm respectively in four points of subcutaneous fat, test-meal group and control group compare after test-meal group self relatively reaches test-meal, and difference has conspicuousness (P＜0.05); Experimenter's exercise tolerance and other healthy index of correlation obviously do not change before and after the test, and got rid of meals and motion influence to weight losing function, according to the criterion in " health food check and assessment technique standard " (version in 2003) of Ministry of Public Health's promulgation, health food soft capsule of the present invention has antiobesity action.
The influence of table 18 pair human body body weight, body fat
| Number | Body weight (kg) | BMI (kg/m 2) | Overweight degree (%) | Body fat total amount (kg) | Body fat percentage (%) | |
| Test group (preceding) | 50 | 81.2±6.6 | 30.0±2.7 | 37.8±16.1 | 26.2±2.8 | 32.3±2.6 |
| Test group (back) | 50 | 79.2±6.4 | 29.3±2.8 | 34.5±16.8 | 24.4±2.7 | 30.9±2.8 |
| The front and back difference | 2.0±2.8 | 0.7±1.0 | 3.3±4.7 | 1.8±1.5 | 1.4±1.4 | |
| Control group (preceding) | 50 | 82.2±5.5 | 29.8±2.4 | 35.5±13.6 | 25.9±2.8 | 31.5±2.3 |
| Control group (back) | 50 | 82.1±5.4 | 29.8±2.4 | 35.4±13.6 | 25.7±2.4 | 31.3±2.1 |
| Pairing t-check (t value) | - | 5.105 | 5.029 | 4.958 | 8.276 | 7.356 |
| Pairing t-check (p value) | - | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |
| T-check (t value) in groups | - | -2.462 | -1.002 | -0.308 | -2.527 | -0.894 |
| T-check (p value) in groups | - | 0.016 | 0.319 | 0.759 | 0.013 | 0.374 |
Notes: the t-that matches compares before and after verifying as test: test group and control group were relatively after t-verified as and tests in groups.
The influence that table 19 pair human body subcutaneous fat thickness and body enclose
Annotate: pairing t-compares before and after verifying as experimental group; Test group and control group were relatively after t-verified as and tests in groups
Claims (2)
1. one kind has the fat-reducing and the health food of anti-oxidation function, it is characterized in that it is to be made by the raw material of following weight parts:
Grape seed extract 5-20 part,
Oolong tea extract 5-20 part,
L-cn 5-20 part,
Wheat-germ oil 20-80 part.
2. the health food with fat-reducing and anti-oxidation function according to claim 1 is characterized in that said health food can be made into soft capsule, hard shell capsules, granule, tablet, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101632860A CN100420391C (en) | 2006-12-18 | 2006-12-18 | Health-care food with anti-oxidation and lowering weight functions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101632860A CN100420391C (en) | 2006-12-18 | 2006-12-18 | Health-care food with anti-oxidation and lowering weight functions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN100998411A CN100998411A (en) | 2007-07-18 |
| CN100420391C true CN100420391C (en) | 2008-09-24 |
Family
ID=38257294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101632860A Expired - Fee Related CN100420391C (en) | 2006-12-18 | 2006-12-18 | Health-care food with anti-oxidation and lowering weight functions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100420391C (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101194691B (en) * | 2007-11-26 | 2011-12-28 | 华东理工大学 | Low calorie foods of nutrition strengthening wheat plantule |
| CN102599502B (en) * | 2012-03-14 | 2013-06-26 | 上海善力健保健食品有限公司 | Healthcare product with weight reducing function and preparation method of healthcare product |
| CN103535574B (en) * | 2012-07-13 | 2015-03-25 | 江苏康缘药业股份有限公司 | Royal jelly composition and preparation method thereof |
| CN103349106A (en) * | 2013-07-22 | 2013-10-16 | 北京绿源求证科技发展有限责任公司 | Food health preserving tea electuary for delaying senescence |
| CN103689433A (en) * | 2013-12-06 | 2014-04-02 | 潘逸东 | Vinous wheat germ flour containing lard oil and preparation method thereof |
| CN107616502A (en) * | 2017-09-20 | 2018-01-23 | 北京军秀咨询有限公司 | A kind of cosmetic slimming nutrition and health care capsule |
| CN107625914A (en) * | 2017-10-16 | 2018-01-26 | 唐宏泉 | A kind of cosmetic slimming nutrition and health care capsule and preparation method thereof |
| CN108095118A (en) * | 2018-01-17 | 2018-06-01 | 长江师范学院 | A kind of slimming health food |
| CN113854559A (en) * | 2021-09-23 | 2021-12-31 | 营养屋(成都)生物医药有限公司 | Weight-losing health food and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106286A (en) * | 1994-02-04 | 1995-08-09 | 湖南省国药开发总公司 | Fat-reducing granules |
| CN1280008A (en) * | 2000-07-27 | 2001-01-17 | 北京北医大医药科技有限责任公司 | Strong anti-oxidative composite capsule of grape seed extract OPC and its producing method |
| CN1460417A (en) * | 2003-06-17 | 2003-12-10 | 吉林市新科奇保健食品有限公司 | Health-care food with immune-regulating and face-beautifying function and its preparation method |
| CN1526330A (en) * | 2003-03-06 | 2004-09-08 | 吉林市新科奇保健食品有限公司 | Health food with functions of delaying senility and regulating immunity and its prepn process |
-
2006
- 2006-12-18 CN CNB2006101632860A patent/CN100420391C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106286A (en) * | 1994-02-04 | 1995-08-09 | 湖南省国药开发总公司 | Fat-reducing granules |
| CN1280008A (en) * | 2000-07-27 | 2001-01-17 | 北京北医大医药科技有限责任公司 | Strong anti-oxidative composite capsule of grape seed extract OPC and its producing method |
| CN1526330A (en) * | 2003-03-06 | 2004-09-08 | 吉林市新科奇保健食品有限公司 | Health food with functions of delaying senility and regulating immunity and its prepn process |
| CN1460417A (en) * | 2003-06-17 | 2003-12-10 | 吉林市新科奇保健食品有限公司 | Health-care food with immune-regulating and face-beautifying function and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100998411A (en) | 2007-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100420391C (en) | Health-care food with anti-oxidation and lowering weight functions | |
| CN100506056C (en) | Slimming tea and preparation method thereof | |
| CN102187887B (en) | Sandwich biscuit with functions of losing weight and regulating blood sugar and production method thereof | |
| Mironenko et al. | Magnesium (Mg, Magnesium)–description, effect on the body, the best sources of magnesium | |
| CN103284039A (en) | Weight-reducing composition and preparation method thereof | |
| CN102885306A (en) | Health-care food composite with function of assisting in reducing blood fat and preparation method thereof | |
| CN108095113A (en) | A kind of composition, preparation and its application with fat reducing blood sugar reducing function | |
| CN102090630A (en) | Health-care product for enhancing antioxidation of human bodies and preparation method thereof | |
| CN101356975B (en) | Health food capable of increasing human immunity and promoting intelligence and strengthening brain and preparation method thereof | |
| CN105727270A (en) | Composition capable of increasing high-density lipoprotein and preventing and treating atherosclerosis and preparing method and application thereof | |
| CN103735556A (en) | Multivitamin mineral composite effervescent tablet and preparation method thereof | |
| CN101356972A (en) | Anti-fatigue anti-hypoxia sports health food | |
| CN111543635A (en) | Health food with weight reducing function and preparation method thereof | |
| CN100393321C (en) | Oral antilipemic liquid and its preparing method | |
| CN104336596A (en) | Medicine composition capable of lowering blood lipid and preparation method thereof | |
| CN103583950A (en) | Wheat cellulose particles and preparation method thereof | |
| CN107669763B (en) | Enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product and preparation method thereof | |
| CN106729123A (en) | A kind of composition of three high drop and preparation method thereof | |
| CN105101817B (en) | Edible composition and preparation method thereof and the food comprising said composition | |
| CN100531783C (en) | Health-care food for reducing blood sugar on the assistant role and its preparing process | |
| KR101266889B1 (en) | Functional food compositions having the recovery effect of blood composition and function | |
| CN101637268B (en) | Health-care food having functions of freckle elimination and radiation resistance and preparation method thereof | |
| CN105995980B (en) | A kind of composition and preparation method thereof with Weight management effect | |
| CN101152236A (en) | Weight-reducing health-care food | |
| CN108812916A (en) | A kind of hunchbacked milk tablet and its preparation with auxiliary hyperglycemic function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JILIN XINKEQI HEALTH-CARE FOOD CO., LTD. Free format text: FORMER OWNER: DONGBEIHU PHARMACEUTICAL CO., LTD. Effective date: 20111231 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20111231 Address after: 132013 Jilin high tech Zone, Jilin Province Road No. three, No. 4 Patentee after: Jilin Xinkeqi Health-care Food Co., Ltd. Address before: 132013 No. 2, No. 3, hi tech Zone, Jilin, Jilin Patentee before: Dongbeihu Pharmaceutical Co., Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 132000 Jilin high tech Zone, Jilin Province Road No. three, No. 4 Patentee after: Jilin cloud Health Food Co., Ltd. Address before: 132013 Jilin high tech Zone, Jilin Province Road No. three, No. 4 Patentee before: Xinkeqi Health Food Co., Ltd., Jilin |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080924 Termination date: 20191218 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |